E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced colorectal carcinoma of UICC stage IV, liver and/or lung metastases only, not optimally resectable |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010036 |
E.1.2 | Term | Colorectal carcinoma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the proportion of patients who achieve surgically complete resectability (S CR) of metastases after preoperative chemotherapy |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the acute and perioperative toxicity of preoperative chemotherapy. • To evaluate the overall survival rate (OS) and progression free survival (PFS)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥18 years 2. Indication: - Histologically confirmed advanced colorectal carcinoma of UICC Stages IV with liver and/or lung only metastases, which are not optimally resectable. - Measurable disease according to RECIST criteria. - In case of liver metastases: 70% liver replacement and/or > 6 segments tumor involved, and/or involvement of all three hepatic veins, and/or involvement of the right and left portal pedical, and/ or involvement of the vena cava. - In case of lung metastases: No tumor with direct infiltration of myocardium, esophageous, spine or intrapericardial large vessels. Preoperative data indicate a significant loss of pulmonary function after pulmonary metastasectomy with severe impairment of quality of life. 3. ECOG performance status of < 2. 4. Life expectancy of > 3 months 5. Laboratory parameters: Proteinuria at baseline: - Patients with proteinuria <2+ on dip¬stick urinalysis. - Patients with 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 h urine collection and must have proteinuria >= 1 g of protein/24 h. The required laboratory values at baseline are as follows: Hematology: º Absolute neutrophil count (ANC) > 1.5 x 109/L º Platelet count > 100 x 109/L º Haemoglobin > 9 g/dL (may be transfused to maintain or exceed this level) º International Normalized Ratio (INR) < 1.5; APTT <1.5 x ULN Biochemistry: º Total bilirubin < 1.5 x upper limit of normal (UNRL) º AST, ALT < 2.5 x UNRL in patients without liver metastases; < 5 x UNRL in patients with liver metastases º Serum creatinine <2.0 mg/dL or 177 1. μmol/L 6. Willingness to give written informed consent, written consent for data protection (legal requirement in Germany: Datenschutzrechtliche Einwilligung) and willingness to participate and to comply with the study.
|
|
E.4 | Principal exclusion criteria |
1. Past or current history of malignancies other than colorectal carcinoma. Patients with curatively treated basal and squamous cell carcinoma of the skin and/or in-situ carcinoma of the cervix are eligible. 2. Previous chemotherapy. 3. Extrahepatic and/or extrapulmonary metastases except of the initially removed lymph node metastases. 4. History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy or history of stroke). 5.Major surgical procedures, open biopsy, or significant traumatic injury within 28 days prior to study treatment start (wound healing has to be completed), or anticipation of the need for major surgical procedure during the course of the study. 6. Evidence of bleeding diathesis or coagulopathy 7. Serious, non-healing wound, ulcer, or bone fracture 8. Treatment with investigational agents or participation in clinical trials within 30 days before study entry. 9. Clinically significant (i.e. active) cardiovascular disease, e.g., uncontrolled hypertension, cerebrovascular accidents (≤ 6 months prior to treatment start), myocardial infarction (≤ 6 months prior to treatment start), unstable angina, New York Heart Association (NYHA) grade >= II, congestive heart failure, serious cardiac arrhythmia requiring medication. 10. Current or recent serious polyneuropathy (grade >= 1 according to NCI CTCAE v3.0 criteria; exception: absence of tendon reflexes). 11. Hemapoetic diseases. 12. Known intra-abdominal inflammatory process or serious gastrointestinal ulceration. 13. Known dihydropyrimidine dehydrogenase (DPD) deficiency. 14. Thromboembolic events or severe hemorrhage (>= 6 months before treatment start). 15. Known hypersensitivity to oxaliplatin, the background medication (bevacizumab, FA or 5-FU) or to their compounds, incl. Chinese hamster ovary (CHO) cell proteins or other recombinant human or humanized antibodies. 16. Known Gilbert-Syndrome 17. Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational regimen or patient at high risk from treatment complications 18. As the following medication(s) can have interactive effects and may interfere with the patient's ability to meet the study requirements, they cannot be administered during the clinical study: - Sorivudin or analog compounds. - Current or recent (within 10 days of first dose of study treatment) treatment with full-dose oral or parenteral anticoagulants or thrombolytic agents (e.g., marcumar therapy) for therapeutic purposes. - Current or recent (within 10 days of first dose of study treatment) chronic use of aspirin (> 325 mg/day) or clopidogrel (> 75 mg/day). 19. Women, lactating, pregnant or of childbearing potential and fertile men not using a highly effective contraceptive method . [Women of childbearing potential must have a negative pregnancy test (serum ßHCG) within 7 days before the first dose of study drug]. 20. Patients who are confined by order of either judicial or administrative authorities (according to § 40 Abs. 1 S. 3 AMG). 21. Patients who are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG). 22. Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study. 23. Patients who possibly are dependent on the sponsor or investigator. 24. Patients who have participated in this study before. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy parameter: S-CR, which is defined as histologically confirmed tumor free resection margins (R0-resection). Secondary efficacy parameter: Progression free overall survival.
Safety parameter: Serious adverse events according to ICH (NCI CTCAE) criteria in terms of all chemotherapy related acute and perioperative toxicities as well as peri- and postsurgical complications. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |